766P Levels of serum EGF concentration as biomarker of response of CIMAvax-EFG vaccine: Survival evaluation of advanced NSCLC patients treated in primary health care scenario

R.A Otiz Carrodeguas,G Lorenzo Monteagudo,P.P Guerra,L Sanchez,L Cárdenas,I Álvarez,E.E Salomón,M Díaz,Y Menéndez,L Lobaina,J.C Columbié,K Camacho,M Corella,N Fardales,J Parra,C Viada,D Saavedra,O Santos,T Crombet Ramos

doi:10.1016/j.annonc.2022.07.892

766P Levels of serum EGF concentration as biomarker of response of CIMAvax-EFG vaccine: Survival evaluation of advanced NSCLC patients treated in primary health care scenario

R.A Otiz Carrodeguas, G Lorenzo Monteagudo + Show 17 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.892

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Center of Molecular Immunology (Cuba)

#Treatment Of Advanced NSCLC Patients #Serum EGF Concentration + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Previous studies have shown that baseline concentrations of EGF in serum could be considered a biomarker of the efficacy of the therapeutic vaccine CIMAVax-EGF. The objective of this study is to evaluate the serum EGF concentration as biomarker of response of CIMAvax-EGF vaccine for the treatment of advanced NSCLC patients in primary health care scenario.

Full Text